Evaxion reports 75% response rate in melanoma vaccine trial
PositiveFinancial Markets

Evaxion has announced a promising 75% response rate in its latest melanoma vaccine trial, marking a significant advancement in cancer treatment. This development is crucial as it offers hope for better outcomes in melanoma patients, a type of skin cancer known for its aggressive nature. The success of this trial could pave the way for more effective therapies and potentially save lives, making it a noteworthy milestone in the fight against cancer.
— Curated by the World Pulse Now AI Editorial System